Nuclera Nucleics Stock

Enzymatic DNA synthesis

Sign up today and learn more about Nuclera Nucleics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Nuclera Nucleics Stock

Nuclera is a next-generation DNA synthesis company creating tailored solutions for the synthetic biology, industrial enzyme engineering, and pharmaceutical industries. Our proprietary enzyme-mediated DNA synthesis platform will enable the rapid and cost-effective production of highly accurate, ultra-long DNA strands. We aim to be the key provider of long-length variant DNA and genome libraries for protein, biological pathway, and ultimately genome-scale engineering.

Funding History

March 2014$500K
April 2014$100K
June 2014$25K
April 2015$203K

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: